H3 Relaxin Demonstrates Antifibrotic Properties via the RXFP1 Receptor
Mechanistic Insights into the Contribution of Epithelial Damage to Airway Remodeling: Novel Therapeutic Targets for Asthma
Relaxin requires the angiotensin II type 2 receptor to abrogate renal interstitial fibrosis
Characterization of a novel model incorporating airway epithelial damage and related fibrosis to the pathogenesis of asthma
